Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C

doi:10.4254/wjh.v7.i26.2688

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5647)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

365

WORD

293

HTML

2603

Figures (1-1)

179

Tables (1-3)

168

Sum=3608

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

982

Download

1057

Sum=2039

Nov 18, 2015 (publication date) through Jul 4, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Hepatol. Nov 18, 2015; 7(26): 2688-2695
Published online Nov 18, 2015. doi: 10.4254/wjh.v7.i26.2688

Table 1 Patient characteristics

	All (n = 253)	SVR (n = 207)	Non-SVR (n = 46)	P value
Sex, male (%)	123 (48.6)	108 (52.2)	15 (32.6)	0.0153
Age (yr)	61 (12.5)	60 (12)	63.5 (11.25)	0.0340
Body mass index (kg/m²)	23.4 (3.9)	23.4 (3.9)	23.9 (3.8)	0.2198
Baseline HCV RNA (log10 IU/mL)	6.5 (0.9)	6.5 (0.9)	6.4 (0.7)	0.4468
IL28B SNP (rs8099917), TT/TG or GG (%)¹	186/65 (74.1/25.9)	166/40 (80.6/19.4)	20/25 (44.4/55.6)	< 0.0001
ITPA SNP (rs1127354), CC/CA or AA (%)¹	193/58 (76.9/23.1)	157/49 (76.2/23.8)	36/9 (80.0/20.0)	0.5802
Hemoglobin level (g/L)	138 (22)	140 (21)	134 (20)	0.0031
Platelet count (× 10⁹/L)	157 (69)	159 (65)	129 (69)	0.0006
Serum albumin (g/L)	40 (6.0)	40 (6.0)	39 (5.0)	0.0143
Aspartate aminotransferase (U/L)	48 (42)	46 (43)	59 (34.5)	0.0350
Alanine aminotransferase (U/L)	54 (58)	53 (64)	58 (44)	0.4955
γ-glutamyl-transpeptidase (U/L)	40 (51)	39 (47)	46 (59)	0.1270
LDL-cholesterol (mg/dL)	95 (38)	98 (36)	75 (35)	< 0.0001
Ferritin (μg/L)	164.6 (232.3)	160.5 (223.2)	181.7 (253.9)	0.3583
Estimated glomerular filtration rate (mL/min per 1.73 m²)	79.4 (19.1)	79.7 (18.9)	77.7 (19.4)	0.6210
Response to previous PegIFN-α/RBV therapy				< 0.0001
Treatment naïve, n (%)	92 (36.4)	81 (39.4)	11 (23.9)
Prior relapse, n (%)	113 (44.7)	100 (48.1)	13 (28.3)
Prior non-response, n (%)	48 (19.0)	26 (12.5)	22 (44.8)
Liver histology
Stage, F0-2/F3-4 (%)	96/58 (62.3/37.7)	87/38 (69.6/30.4)	9/20 (31.0/69.0)	< 0.0001
Grade, A0-1/A2-3 (%)	54/100 (35.1/64.9)	45/80 (36.0/64.0)	9/20 (31.0/69.0)	0.614
Not determined, n	99	82	17

¹IL28B and ITPA SNPs were not available for only two patients (1.2%). Continuous variables are expressed as median (interquartile range). P value draws a comparison between SVR and non-SVR patients. SVR: Sustained virological response; HCV: Hepatitis C virus; IL28B: Interleukin 28B; SNP: Single-nucleotide polymorphism; ITPA: Inosine triphosphate pyrophosphatase; LDL: Low-density lipoprotein; PegIFN: Pegylated interferon; RBV: Ribavirin.

Citation: Hiramine S, Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World J Hepatol 2015; 7(26): 2688-2695
URL: https://www.wjgnet.com/1948-5182/full/v7/i26/2688.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i26.2688